JP2019525910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525910A5 JP2019525910A5 JP2018568685A JP2018568685A JP2019525910A5 JP 2019525910 A5 JP2019525910 A5 JP 2019525910A5 JP 2018568685 A JP2018568685 A JP 2018568685A JP 2018568685 A JP2018568685 A JP 2018568685A JP 2019525910 A5 JP2019525910 A5 JP 2019525910A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- acid
- compound
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 19
- 102000001398 Granzyme Human genes 0.000 claims 13
- 108060005986 Granzyme Proteins 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 11
- 239000012216 imaging agent Substances 0.000 claims 11
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 238000003384 imaging method Methods 0.000 claims 8
- 125000005647 linker group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052720 vanadium Inorganic materials 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 4
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229960003330 pentetic acid Drugs 0.000 claims 4
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 3
- 239000010949 copper Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 claims 2
- RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 claims 2
- GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 claims 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- CYJYKTMBMMYRHR-UHFFFAOYSA-N acetic acid;1,4,7-triazonane Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.C1CNCCNCCN1 CYJYKTMBMMYRHR-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims 2
- 229960004657 indocyanine green Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000005298 paramagnetic effect Effects 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 108010054624 red fluorescent protein Proteins 0.000 claims 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 229910052727 yttrium Inorganic materials 0.000 claims 2
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 claims 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 1
- 229910052692 Dysprosium Inorganic materials 0.000 claims 1
- 229910052691 Erbium Inorganic materials 0.000 claims 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 229910052689 Holmium Inorganic materials 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims 1
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 claims 1
- 238000012879 PET imaging Methods 0.000 claims 1
- -1 REG Chemical compound 0.000 claims 1
- 229910052771 Terbium Inorganic materials 0.000 claims 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims 1
- 229910052769 Ytterbium Inorganic materials 0.000 claims 1
- RUSUZAGBORAKPY-UHFFFAOYSA-N acetic acid;n'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCNCCNCCN RUSUZAGBORAKPY-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000005529 alkyleneoxy group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 239000011651 chromium Substances 0.000 claims 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 claims 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims 1
- 238000013170 computed tomography imaging Methods 0.000 claims 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical compound [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 claims 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 claims 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 claims 1
- 239000002096 quantum dot Substances 0.000 claims 1
- 229910052702 rhenium Inorganic materials 0.000 claims 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022143354A JP2023002508A (ja) | 2016-07-01 | 2022-09-09 | グランザイムｂを指向するイメージングおよび治療 |
| JP2025014429A JP2025081347A (ja) | 2016-07-01 | 2025-01-31 | グランザイムｂを指向するイメージングおよび治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357845P | 2016-07-01 | 2016-07-01 | |
| US62/357,845 | 2016-07-01 | ||
| US201662435541P | 2016-12-16 | 2016-12-16 | |
| US62/435,541 | 2016-12-16 | ||
| PCT/US2017/040212 WO2018005926A1 (en) | 2016-07-01 | 2017-06-30 | Granzyme b directed imaging and therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143354A Division JP2023002508A (ja) | 2016-07-01 | 2022-09-09 | グランザイムｂを指向するイメージングおよび治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525910A JP2019525910A (ja) | 2019-09-12 |
| JP2019525910A5 true JP2019525910A5 (cg-RX-API-DMAC7.html) | 2020-08-06 |
| JP7194595B2 JP7194595B2 (ja) | 2022-12-22 |
Family
ID=60787787
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568685A Active JP7194595B2 (ja) | 2016-07-01 | 2017-06-30 | グランザイムｂを指向するイメージングおよび治療 |
| JP2022143354A Pending JP2023002508A (ja) | 2016-07-01 | 2022-09-09 | グランザイムｂを指向するイメージングおよび治療 |
| JP2025014429A Pending JP2025081347A (ja) | 2016-07-01 | 2025-01-31 | グランザイムｂを指向するイメージングおよび治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143354A Pending JP2023002508A (ja) | 2016-07-01 | 2022-09-09 | グランザイムｂを指向するイメージングおよび治療 |
| JP2025014429A Pending JP2025081347A (ja) | 2016-07-01 | 2025-01-31 | グランザイムｂを指向するイメージングおよび治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11559590B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3478162B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7194595B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018005926A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241511B2 (en) * | 2016-12-29 | 2022-02-08 | The General Hospital Corporation | HER3 peptides for imaging and radiotherapy |
| US11667645B2 (en) | 2018-02-13 | 2023-06-06 | Cytosite Biopharma Inc. | Granzyme B directed imaging and therapy |
| WO2021252664A1 (en) * | 2020-06-09 | 2021-12-16 | Cytosite Biopharma Inc. | Granzyme b directed imaging and therapy |
| CN114075263B (zh) * | 2020-08-18 | 2023-09-19 | 中南大学湘雅三医院 | 一种近红外分子探针及其制备和在检测颗粒酶b中的应用 |
| CN113512090A (zh) * | 2021-04-30 | 2021-10-19 | 复旦大学附属肿瘤医院 | 一种颗粒酶b结合化合物及其前体化合物和用途 |
| CN114028590B (zh) * | 2021-11-18 | 2022-09-06 | 北京大学 | 颗粒酶b靶向配合物、放射性药物及其制备方法和应用 |
| JP2025501465A (ja) * | 2021-12-08 | 2025-01-22 | サイトサイト バイオファーマ インコーポレイテッド | グランザイムｂに特異的な化合物及びその使用 |
| JP2024546710A (ja) * | 2021-12-08 | 2024-12-26 | サイトサイト バイオファーマ インコーポレイテッド | グランザイムｂに特異的な化合物のためのプロドラッグ及びその使用 |
| JPWO2024143314A1 (cg-RX-API-DMAC7.html) * | 2022-12-27 | 2024-07-04 | ||
| CN116589527B (zh) * | 2023-04-25 | 2023-12-12 | 北京大学第一医院 | 一种颗粒酶b靶向抑制剂及核医学探针与应用 |
| WO2024228936A1 (en) * | 2023-05-03 | 2024-11-07 | Merck Sharp & Dohme Llc | Cyclic peptides as pet imaging agents of granzyme b |
| TW202508601A (zh) * | 2023-06-07 | 2025-03-01 | 美商塞托賽特生物製藥股份有限公司 | 對顆粒酶ｂ具有特異性之化合物之前驅藥及其用途 |
| WO2025226524A1 (en) * | 2024-04-23 | 2025-10-30 | Merck Sharp & Dohme Llc | Granzyme b pet imaging agents |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US7011816B2 (en) * | 2001-12-26 | 2006-03-14 | Immunomedics, Inc. | Labeling targeting agents with gallium-68 and gallium-67 |
| US7927871B2 (en) * | 2002-01-29 | 2011-04-19 | Oncoimmunin, Inc. | Visualization and quantitation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers |
| WO2003065987A2 (en) | 2002-02-04 | 2003-08-14 | Merck & Co., Inc. | Granzyme b inhibitors |
| ATE457349T1 (de) | 2002-08-23 | 2010-02-15 | Multhoff Gabriele Prof Dr | Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen |
| WO2005117928A1 (en) | 2004-05-30 | 2005-12-15 | Cemines, Inc. | Compositions and methods for the treatment of skin cancer |
| US20080311036A1 (en) | 2005-05-11 | 2008-12-18 | University Of Florida Research Foundation, Inc. | Imaging of Neural and Organ Injury or Damage |
| JP2009509979A (ja) | 2005-09-29 | 2009-03-12 | ユニバーシティ オブ アルバータ | グランザイムｂ阻害のための組成物および方法 |
| CA2739512A1 (en) | 2007-10-01 | 2009-04-09 | The University Of British Columbia | Granzyme a and granzyme b diagnostics |
| US20100068151A1 (en) * | 2008-03-11 | 2010-03-18 | Rosenblum Michael G | Multimodality molecular imaging with therapeutic conjugates |
| JP2012513591A (ja) * | 2008-12-22 | 2012-06-14 | ザ チルドレンズ リサーチ インスティテュート | 敗血症の検出のための方法 |
| US9290794B2 (en) * | 2010-05-11 | 2016-03-22 | Promega Corporation | Mutant protease biosensors with enhanced detection characteristics |
| NZ612533A (en) * | 2010-12-06 | 2015-03-27 | Univ British Columbia | Granzyme b inhibitor compositions, methods and uses for promoting wound healing |
| CA2908315A1 (en) * | 2013-03-29 | 2014-10-02 | Vida Therapeutics, Inc. | Cosmetic uses and methods for indoline granzyme b inhibitor compositions |
| KR101552943B1 (ko) | 2013-03-29 | 2015-09-14 | 한양대학교 산학협력단 | 형광공명에너지전이 현상을 이용한 면역반응 영상화 |
| DK3417058T3 (da) * | 2016-02-16 | 2021-11-15 | Res Found Dev | Sortase-modificerede molekyler og anvendelser deraf |
-
2017
- 2017-06-30 WO PCT/US2017/040212 patent/WO2018005926A1/en not_active Ceased
- 2017-06-30 US US16/314,134 patent/US11559590B2/en active Active
- 2017-06-30 JP JP2018568685A patent/JP7194595B2/ja active Active
- 2017-06-30 EP EP17821330.2A patent/EP3478162B1/en active Active
-
2022
- 2022-09-09 JP JP2022143354A patent/JP2023002508A/ja active Pending
-
2023
- 2023-01-05 US US18/150,542 patent/US12246075B2/en active Active
-
2025
- 2025-01-31 JP JP2025014429A patent/JP2025081347A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019525910A5 (cg-RX-API-DMAC7.html) | ||
| US20230348535A1 (en) | Radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer | |
| CN111285918B (zh) | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 | |
| JP6814234B2 (ja) | 部位特異的ｕＰＡＲ標的化のための１７７−Ｌｕ標識ペプチド | |
| JP2020521021A5 (cg-RX-API-DMAC7.html) | ||
| JP6661010B2 (ja) | ペプチドチオ尿素誘導体、これを含有する放射線同位体標識化合物、およびこれを活性成分として含有する前立腺癌を処置または診断するための医薬組成物 | |
| Ciesienski et al. | Fibrin-targeted PET probes for the detection of thrombi | |
| JP2025081347A (ja) | グランザイムｂを指向するイメージングおよび治療 | |
| RU2019139432A (ru) | Фармакокинетическая оптимизация бифункциональных хелатов и их применение | |
| JP2011519348A5 (cg-RX-API-DMAC7.html) | ||
| US20030171561A1 (en) | Aminocarboxylate ligands having substituted aromatic amide moieties | |
| Chen et al. | Radioactive nanomaterials for multimodality imaging | |
| US20150359913A1 (en) | Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides | |
| US9200017B2 (en) | Multimodal imaging of fibrin | |
| JP2011519367A5 (cg-RX-API-DMAC7.html) | ||
| JP2025063147A5 (cg-RX-API-DMAC7.html) | ||
| US20200206358A1 (en) | Long-circulating theranostic agents for diagnosing and imaging metastatic tumors | |
| RU2007118548A (ru) | Соединение для визуализации перфузии миокарда | |
| CN104189924B (zh) | 一种以碳基材料为支架的磁共振造影剂及其制备方法 | |
| CN102727911B (zh) | 双氨基聚乙二醇修饰的顺磁性金属配合物磁共振成像造影剂 | |
| RU2013113677A (ru) | Визуализирующие апоптоз агенты на основе лантибиотических пептидов | |
| RU2018115734A (ru) | Полипептиды антител и их применение | |
| JP2022520798A (ja) | アミラーゼ切断可能なリンカーを含む前立腺特異的膜抗原（ｐｓｍａ）リガンド | |
| RU2015137856A (ru) | Иммунологическое визуализирующее средство для использования при терапии конъюгатом антитело-лекарственное средство | |
| BASACO et al. | COPPER-61 IS AN ADVANTAGEOUS ALTERNATIVE TO GALLIUM-68 FOR PET IMAGING OF SOMATOSTATIN RECEPTOR-EXPRESSING TUMORS: A HEAD-TO-HEAD COMPARATIVE PRECLINICAL STUDY |